PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) belongs to an intracellular invertase or decarboxylase and is an independent risk factor for atherosclerosis (AS). This study aimed to investigate the therapeutic potential of the PCSK9 inhibitor, inclisiran, and its underlying mechan...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Ni, Xu, Qin, Cui, Wei, Feng, Xiaoying, Gao, Huijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761140/
https://www.ncbi.nlm.nih.gov/pubmed/36544639
http://dx.doi.org/10.21037/atm-22-4652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761140/
https://www.ncbi.nlm.nih.gov/pubmed/36544639
http://dx.doi.org/10.21037/atm-22-4652

Ejemplares similares